Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.6)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2009, vol. 18, nr 5, September-October, p. 473–479

Publication type: original article

Language: English

Is There a Relationship Between Aspirin Responsiveness and Clinical Aspects of Ischemic Stroke?

Czy istnieje związek między odpowiedzią na aspirynę a klinicznymi aspektami udaru niedokrwiennego mózgu

Anna B. Sobol1,, Alina Mochecka2,, Krzysztof Selmaj2,, Jerzy Loba1,

1 Department of Diabetology and Metabolic Diseases, Medical University of Lodz, Poland

2 Department of Neurology, Medical University of Lodz, Poland

Abstract

Background. The issue of aspirin responsiveness in ischemic stroke patients is still unresolved.
Objectives. The aim of the study was to determine whether aspirin responsiveness is related to the clinical status of stroke.
Material and Methods. Platelet response to acetylsalicylic acid (ASA) was assessed in 64 patients (41 men, mean age: 57.9 ± 10.4 years) with ischemic stroke or transient ischemic attack receiving the routine dose of 150 mg of ASA daily. Platelet reactivity was assessed using a platelet function analyzer (PFA−100) with collagen/epinephrine cartridges and by whole−blood platelet aggregometry with 0.5 mM arachidonic acid on the first day of acute stroke and after 10 days of ASA intake.
Results. Of the 64 patients, 23 (36%) were ASA unresponsive as assessed by the platelet reactivity tests. Based on the Rankin Scale (of 1–5), significantly worse neurological status was observed in the group of grade−3 ASA−unresponsive compared with grade−2 ASA−responsive patients 10 days after stroke occurrence (p = 0.02). In all the ASA−unresponsive patients, clinical worsening and/or computed tomography signs of progression before modification of the antiplatelet and/or antithrombotic treatment were observed.
Conclusion. These findings suggest that assessment of ASA response might be a predictive factor in stroke prognosis and therapy.

Streszczenie

Wprowadzenie. Problem odpowiedzi na aspirynę u pacjentów z niedokrwiennym udarem mózgu pozostaje przedmiotem dyskusji.
Cel pracy. Zbadanie, czy odpowiedź na aspirynę jest związana z klinicznym przebiegiem niedokrwiennego udaru mózgu.
Materiał i metody. Oceniano reakcję płytek krwi na kwas acetylosalicylowy (ASA) u 64 pacjentów (41 M, średnia wieku 57,9 ± 10,4 lat) z niedokrwiennym udarem mózgu lub przejściowym atakiem niedokrwiennym (TIA), otrzymujących rutynową dawkę ASA dziennie. Reaktywność płytek krwi oceniano za pomocą analizatora czynności płytek krwi (PFA−100TM) z użyciem kartridży kolagen/epinefryna i na podstawie pomiaru agregacji we krwi pełnej z 0,5 mM kwasem arachidonowym w pierwszym dniu wystąpienia udaru i po 10 dniach przyjmowania 150 mg ASA.
Wyniki. Wśród 64 pacjentów – 23 (36%) nie wykazywało odpowiedzi na ASA na podstawie oceny reaktywności płytek. Zgodnie z oceną neurologiczną według skali Rankina, po 10 dniach trwania udaru obserwowano statystycznie istotny gorszy stan neurologiczny w grupie pacjentów nieodpowiadających na ASA 3 (1–5) w porównaniu z grupą pacjentów z prawidłową odpowiedzią na ASA 2 (1–5) (p = 0,02). U wszystkich pacjentów nieodpowiadających na ASA obserwowano kliniczne pogorszenie i/lub cechy progresji w badaniu tomografii komputerowej przed modyfikacją leczenia przeciwpłytkowego lub przeciwzakrzepowego.
Wnioski. Badania własne sugerują, że ocena odpowiedzi na ASAmoże być czynnikiem predykcyjnym w rokowaniu i leczeniu udaru mózgu.

Key words

acetylsalicylic acid, antiplatelet therapy, aspirin responsiveness, ischemic stroke

Słowa kluczowe

kwas acetylosalicylowy, leczenie przeciwpłytkowe, niedokrwienny udar mózgu, odpowiedź na aspirynę

References (30)

  1. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989, 321, 129–135.
  2. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992, 268, 1292–1300.
  3. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trial of antiplatelet therapy – I; prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308, 81–106.
  4. Hovens MM, Snoep JD, Eikelboom JC, van der Bom JG, Mertens BJ, Huisman MV: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007,153, 175–181.
  5. Patrono C: Aspirin resistance: definition, mechanisms and clinical read−outs. J Thromb Haemost 2003, 1, 1710–1713.
  6. Zimmermann N, Hohlfeld T: Clinical implications of aspirin resistance. Thromb Haemost 2008, 100, 379–390.
  7. National Institute of Neurological Disorders and Stroke Ad Hoc Committee. Classification of cerebrovascular diseases III. Stroke 1990, 21, 637–676.
  8. Rankin J: Cerebral vascular accidents in patients over the age of 60, I: general considerations. Scott Med J 1957, 2, 127–136.
  9. Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schroer K, Siebler M: Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007, 24, 43–50.
  10. Hung J, Lam JY, Lacoste L, Letchacovski G: Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995, 92, 2432–2436.
  11. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F: Inhibition of platelet aggregation by aspirin progressively decreases in long−term treated patients. J Am Coll Cardiol 2004, 43, 979–984.
  12. Cerletti C, Dell’Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003, 42, 1059–1070.
  13. Santos MT, Valles J, Lago A, Tembl J, Sanchez E, Moscardo A, Cosin J: Residual platelet thromboxane A2 and prothrombotic effects of erythrocyte are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008, 6, 615–621.
  14. Maclouf J, Folco G, Patrono C: Eicosanoids and iso−eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998, 79, 691–705.
  15. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutations within the cyclooxygenase−1 gene in aspirin non−responders with recurrence of stroke. Thromb Res 2003, 112, 275–283.
  16. Zytkiewicz M, Giełwanowska L, Wojtasińska E, Psuja P, Zawilska K: Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008, 11, 727–733.
  17. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A: Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001, 104, 2666–2672.
  18. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM: Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009, 101, 123–133.
  19. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A: Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006, 113, 31–35.
  20. Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006, 21 (suppl 1), 7–16.
  21. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Magnat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25, 2331–2336.
  22. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non−responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250, 63–66.
  23. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM: Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischemic stroke and TIA. Platelets 2005, 16, 269–280.
  24. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin−resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105, 1650–1655.
  25. Englyst NA, Horsfield G, Kwan J, Byrne CD: Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008, 28, 1196–1203.
  26. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry−Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators: Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49, 1982–1988.
  27. Snoep JD, Hovens MM, Eikelboom JC, van der Bom JG, Huisman MV: Association of laboratory−defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta−analysis. Arch Intern Med 2007, 167, 1593–1599.
  28. Krasopoulus G, Brister SJ, Beattie WS, Buchanan MR: Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta−analysis. BMJ 2008, 336, 195–198.
  29. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H: Unstable angina, stroke, myocardial infarction and death in aspirin non−responders. A prospective, randomized trial. The ASCET (Aspirin non−responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004, 38, 353–356.
  30. Patrono C, Rocca B: Aspirin: promise and resistance in the millennium. Arterioscler Thromb Vasc Biol. 2008, 28, 25–32.